You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
亞盛醫藥-B(06855.HK)四項研究成果亮相2023年美國臨牀腫瘤學會(ASCO)年會
格隆匯 04-27 07:42

格隆匯4月27日丨亞盛醫藥-B(06855.HK)發佈公吿,公司共四項臨牀研究入選 2023年美國臨牀腫瘤學會(ASCO)年會,涉及中國首個且唯一獲批上市的第三代 BCR-ABL抑制劑奧雷巴替尼(HQP1351;商品名:耐立克®)、Bcl-2選擇性抑制劑APG-2575、MDM2-p53抑制劑APG-115,和FAK/ALK/ROS1三聯抑制劑APG2449四個重點品種。

根據披露,一年一度的ASCO年會是全球腫瘤領域最重要的、最為權威的學術交流盛會,將展示當前國際最前沿的臨牀腫瘤學科研成果和腫瘤治療技術。本屆ASCO年會將於2023年6月2日至2023年6月6日(美國當地時間)在美國伊利諾伊州芝加哥 McCormick會議中心以線上線下結合的形式舉辦。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account